Effectiveness Assessment of Riluzole in the Prevention of Oxaliplatin-induced Peripheral Neuropathy.

Oxaliplatin-induced Peripheral Neuropathy Clinical Trial

— RILUZOX-01  

Official title:

Effectiveness Assessment of Riluzole in the Prevention of Oxaliplatin-induced Peripheral Neuropathy: A Phase II Randomized Study by UNICANCER With the Cooperation of AFSOS

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03722680
• Other study ID #: UC-0106/1712
• Secondary ID: 2017-002320-25
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: October 28, 2020
• Est. completion date: October 28, 2024

Study information

• Verified date: November 2023
• Source: UNICANCER
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

It is a phase II trial, randomized, parallel, double blind, multicenter, comparing riluzole versus placebo.

The trial population is composed of patients ≥18 years old that have developed stage II/III colorectal cancer and are eligible for Simplified FOLFOX4 (6-12 cycles) adjuvant chemotherapy.

The primary objective is to assess the preventive efficacy of riluzole on the severity of oxaliplatin-induced peripheral neuropathy during the Simplified FOLFOX4 adjuvant chemotherapy of stage II/III colorectal cancers.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 80
• Est. completion date: October 28, 2024
• Est. primary completion date: September 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients aged = 18 years old,

2. Eligible patient starting adjuvant oxaliplatin-based chemotherapy (6-12 cycles, Simplified FOLFOX4) for stage II/III colorectal cancer,

3. Histological or cytological confirmation of colorectal cancer,

4. Performance status (ECOG) =2,

5. Normal hematological function (ANC =1.5 x 10?/L; platelets count =100 x 10?/L; hemoglobin =9.0 g/dL),

6. Normal hepatic function: total bilirubin =1.5 x upper limit of normal (ULN) (unless documented Gilbert's syndrome); aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT) =3 x ULN, and gamma-glutamyltransferase (GGT) =3 x ULN,

7. Normal renal function: serum creatinine =1.5 x ULN,

8. Normal cardiac function: ECG,

9. Patients affiliated to the French national health insurance,

10. Patient must have signed a written informed consent form prior to any study specific procedures,

11. French language comprehension,

12. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.

Exclusion Criteria:

1. Metastatic cancer,

2. Diagnosis of neuropathy,

3. EORTC QLQ-CIPN20 sensory score >6,

4. Previous neurotoxic chemotherapy treatment,

5. Patients with chronic obstructive pulmonary disease,

6. ALAT/ASAT elevated more than 3 times the normal value,

7. Patients with known allergy or severe hypersensitivity to riluzole or any of the study drug excipients,

8. Dependence on alcohol or drugs,

9. Psychotic disorders,

10. Women pregnant or breastfeeding,

11. Patients undergoing a measure of legal protection (trusteeship, guardianship ...).

Related Conditions & MeSH terms

• Oxaliplatin-induced Peripheral Neuropathy
• Peripheral Nervous System Diseases

Intervention

Drug:
• Riluzole
Riluzole during chemotherapy (oxaliplatin)
• Placebo Oral Tablet
placebo

Locations

Country	Name	City	State
France	ICO - Site Paul Papin	Angers
France	CH Beauvais	Beauvais
France	Centre François Baclesse	Caen
France	Hia Percy	Clamart
France	CHU de Clermont -Ferrand	Clermont-Ferrand
France	Clinique St Côme	Compiègne
France	GHPSO	Creil
France	Centre Georges François Leclerc	Dijon
France	CHU de Dijon	Dijon
France	CH Annecy-Genevois	Pringy
France	CHU de Reims	Reims
France	Institut Jean Godinot	Reims
France	ICO - Site René Gauducheau	Saint-Herblain
France	Hia Begin	Saint-Mandé
France	CHU de Saint-Etienne	Saint-Priest
France	Hôpital Foch	Suresnes

Sponsors (1)

Lead Sponsor	Collaborator
UNICANCER

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Quality of life questionnaire-chemotherapy-induced peripheral neuropathy (QLQ-CIPN20)	QLQ-CIPN20 Questionnaire (EORTC): Self-reported questionnaire consisting of 20 questions that assess the symptoms and functional limitations of chemotherapy-induced peripheral neuropathy. The questionnaire is divided in 3 subscales: sensory, motor, and autonomic and gives a comprehensive picture of the nature, frequency, and severity of chemotherapy-induced peripheral neuropathy (CIPN). Using a 4-point Likert scale (1 = "not at all," 2 = "a little," 3 = "quite a bit," and 4 = "very much"), patients indicate the degree to which they have experienced sensory, motor, and autonomic symptoms.	3 months afer initiation of oxaliplatin based chemotherapy (1 cycle = 14 days)
Secondary	QLQ-CIPN20	Self-reported questionnaire consisting of 20 questions that assess the symptoms and functional limitations of chemotherapy-induced peripheral neuropathy. The questionnaire is divided in 3 subscales: sensory, motor, and autonomic and gives a comprehensive picture of the nature, frequency, and severity of CIPN. Using a 4-point Likert scale (1 = "not at all," 2 = "a little," 3 = "quite a bit," and 4 = "very much"), patients indicate the degree to which they have experienced sensory, motor, and autonomic symptoms.	At inclusion (V0), 3 months (V2), up to 7 months (V3), up to 9 months (V4), up to 12 months (V5), up to 15 months (V6), and up to 18 months (V7) after initiation of oxaliplatin based chemotherapy.
Secondary	National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0	The NCI-CTCAE v5.0 is widely accepted in the community of oncology research as the leading rating scale for adverse events. This scale will assess the severity of sensory neuropathic disorders, this derivative into 5 grades determined by the investigator.	throughout study completion, assessed up to 43 months
Secondary	Brief Pain Inventory (BPI) questionnaire	This self-report questionnaire includes: A body schema; The maximum pain, lowest pain, usual pain within the last 15 days (Numerical Numeric rating scales (NRS) 0 to 10; Description of current analgesic treatment,; An assessment of relief by a percentage scale (0-100%), Assessment of the impact of pain on: mood, relationships with others, walking, sleep, work, happiness the joy - of living, recreation, activities in general (digital scales, rating from 0 [normal] to 10 [no activity]).	At inclusion (V0), 3 months (V2), up to 7 months (V3), up to 9 months (V4), up to 12 months (V5), up to 15 months (V6), and up to 18 months (V7) after initiation of oxaliplatin based chemotherapy.
Secondary	Douleur Neuropathique 4 (DN4) questionnaire (interview portion)	The interview portion of the DN4 questionnaire is a clinician-administered screening tool for neuropathic pain. The questionnaire includes 7 items, grouped into two questions. Each item, is answered as either YES or NO. A final cumulative patient's score is obtained by allocating 1 point for each YES and 0 point for each NO. If the patient's score is =3/7, the test is positive.	This evaluation will be carried out only if the item 5 of BPI "general pain felt in the last 7 days" is =4/10.
Secondary	Neuropathic Pain Symptom Inventory (NPSI) questionnaire	This self-reported questionnaire assesses different neuropathic pain symptoms. The French NPSI includes 12 items that discriminates and quantifies five distinct dimensions of neuropathic pain. Each of these items are quantified on a (0-10) numerical scale.	This evaluation will be carried out only if the item 5 of BPI "general pain felt in the last 7 days" is =4/10.
Secondary	QLQ-C30 questionnaire (EORTC)	This self-reported questionnaire assesses the health-related quality of life of cancer patients in clinical trials.; The questionnaire includes five functional scales (physical, everyday activity, cognitive, emotional, and social), three symptom scales (fatigue, pain, nausea and vomiting), a health/quality of life overall scale, and a number of additional elements assessing common symptoms (including dyspnea, loss of appetite, insomnia, constipation, and diarrhea), as well as, the perceived financial impact of the disease.; All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.	At inclusion (V0), 3 months (V2), up to 7 months (V3), up to 9 months (V4), up to 12 months (V5), up to 15 months (V6), and up to 18 months (V7) after initiation of oxaliplatin based chemotherapy.
Secondary	Disease progression	Disease Free Survival, defined as the interval between the date of randomization and the date of cancer relapse (local, regional, metastases, second cancer) or death from any cause, whichever occurs first.	From date of randomisation until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 43 months.
Secondary	Time to HRQoL score deterioration	The interval between randomization and deterioration =5 points in the HRQoL score as compared to baseline score or death (all causes).	At inclusion (V0), 3 months (V2), up to 7 months (V3), up to 9 months (V4), up to 12 months (V5), up to 15 months (V6), and up to 18 months (V7) after initiation of oxaliplatin based chemotherapy.
Secondary	Quantification of chemotherapy dose reductions	The number of chemotherapy dose reduction caused by severe neuropathy and/or poor tolerance of treatment will be recorded.	3 months (V2) and up to 7 months (V3) after initiation of oxaliplatin based chemotherapy.
Secondary	Quantification of cumulative dose	The cumulative dose (mg/m²) of chemotherapy delivered to patients will be recorded.	3 months (V2) and up to 7 months (V3) after initiation of oxaliplatin based chemotherapy.
Secondary	Evaluation of study exit rates	The study exit rate caused by severe neuropathy and/or poor tolerance of treatment will be recorded.	3 months (V2) and up to 7 months (V3) after initiation of oxaliplatin based chemotherapy.
Secondary	Assessment of glutamate serum level	Correlation with colorectal cancer tumors/nodes/metastases (TNM) score (and eventually neuropathic symptoms), glutamate plasmatic	Glutamate serum level will be dose at inclusion (V0), 3 months (V2), up to 7 months (V3), and up to 18 months (V7) after initiation of oxaliplatin based chemotherapy.